The Transformation of
Undruggable Targets Towards
Through Regulation of Gene Expression
- 22 Sep 2021
- One of the founders of Epigeneron, Inc., Toshitsugu Fujita, Ph.D. received Bioindustry Research Award 2021.
- 03 Sep 2021
- FUJIFILM Wako Pure Chemical Corporation was designated as one of the distributors of the ORNi-PCR related products.
The regulation of gene expression, which includes epigenetic mechanisms, is a growing research area for industrial and academic interests in discovering novel drug targets.
Science & Technologies
Novel target discovery using
DNA is associated with proteins and RNAs to form chromatin which regulates gene functions such as epigenetic regulation and transcription. Comprehensive understanding of chromatin and the mechanisms of such genome functions requires the identification of molecules that bind to the genomic regions of interest in vivo.
ORNi-PCR to detect rare target
DNA sequence variants are known to be involved in the emergence of intractable diseases such as cancer. Various methods using PCR have been employed to detect the presence or absence of DNA mutations known to cause these diseases. However, conventional PCR-based methods have several limitations, such as sensitivity, cost, and ability to provide a definitive diagnosis.